Las hiperlipemias y la prevención primaria de la cardiopatía isquémica

Medicina Clinica

Volumn 109, Issue 14, 1997, Pages 549-552

  Gérvas, Juan ^a,b   Fernández, Mercedes Pérez ^a,c  

^a Equipo CESCA   (Spain)

^b rea 5   (Spain)

^c IMSALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FEMALE; HEALTH PROMOTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; REVIEW; RISK FACTOR;

FEMALE; HEALTH PROMOTION; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 84855687599     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Consenso para el control de la colesterinemia en España. Madrid: Ministerio de Sanidad y Consumo, 1989.
2. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recomendations of the European Atheroclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992; 2: 113-156.
3. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3.015-3.023.
4. Sociedad Española de Arteriosclerosis, Sociedad Española de Medicina Interna y Liga de la Lucha contra la Hipertensión Arterial. Recomendaciones para la prevención primaria de la enfermedad cardiovascular. Clin Invest Arteriosclerosis 1994; 6: 62-102.
5. Sociedad Española de Arteriosclerosis y Sociedad Espanola de Cardiología. Evidencias clinico-experimentales y recomendaciones para el tratamiento de la hiperlipidemia en pacientes con cardiopatía isquémica. Clin Invest Arteriosclerosis 1994; 6: 103-111.
6. Oliver M, Poole-Wilson P, Shepherd J, Tikkane M. Lower patients' cholesterol now. Trial evidence shows clear benefits from secondary prevention. Br Med J 1995; 310: 1.280-1.281.
7. Skrabanek P, McCormick J. Sofismas y desatinos en Medicina. Barcelona: Doyma, 1992.
8. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995; 332: 1.491-1.498.
9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1.301-1.307.
10. Alexander W. Lowering cholesterol does pay off. Patient Care 1994; 29: 23.
11. Scandinavian Simvastatin Survival Group. Radomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1.383-1.389.
12. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1.274-1.275.
13. Plans P, Rovira J. Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes. Med Clin (Barc) 1995; 105: 327-333.
14. Gil VF, Buhigués F, Pedrera V, Medina E, Tevar A, Quirce F et al. Importancia de la determinación del colesterol en la valoración del riesgo coronario en la práctica clinica. Aten Primaria 1995; 16: 254-260.
15. Brea AJ, Villar MA, Mosquera JD, Ramirez MV. Opiniones de los médicos de atención primaria de La Rioja sobre el tratamiento de las hiperlipidemias. Med Clin (Barc) 1996; 106: 409-413.
16. Cochrane AL. Eficacia y eficiencia. Reflexiones al azar sobre los servicios sanitarios. Barcelona: Salvat, 1985.
17. Saura J. Indicadores de calidad de la prescripción: el índice UTB, ¿un indicador inadecuado para la atención primaria? Jano 1995; 49: 576.
18. Anton̄anzas A, Castillo M, Esteban MC, Estebanell MP, Garcia-Pellicer MP, Ostale MA. Diferencias de criterio entre cinco consensos sobre colesterol. MEDIFAM 1992; 2: 85-90.
19. Corral C. Prevención primaria de la cardiopatía isquémica. ¿Cuál es el lugar de la intervención farmacológica? Med Clin (Barc) 1991; 96: 388-393.
20. Balaguer I. Colesterol: más allá de los consensus. Jano 1993; 44: 151-157.
21. Dixon AS. The evolution of clinical policies. Mec Care 1990; 28: 201-220.
22. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. Br Med J 1992; 305: 15-19.
23. Lipid Research Clinics Program. The Lipid Research Clinics coronary prevention trials results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
24. Miettinen T,A Huttunen JK, Naukkarinen V. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence and mortality. JAMA 1985; 254: 2.097-2.103.
25. Verschuren WMM, Jacobs DR, Bloemberg BPM, Kromhout D, Menotti A, Aravanis CH et al. Serum total cholesterol and long-term coronary heart disease in different cultures. Twenty-five yearts follow-up of the seven countries study. JAMA 1995; 274: 131-136.
26. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease [carta]. Lancet 1996; 347: 468-469.
27. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995; 345: 1.616-1.619.
28. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1.467-1.471.
29. McCormick J. Gemfibrozil and coronary heart disease. N Engl J Med 1988; 318: 1.274.
30. Brett AS. Treating hypercholesterolemia. How should practicing physicians interpret the published data for patients? N Engl J Med 1989; 321: 676-680.
31. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trials results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992; 117: 916-921.
32. Laupacis A, Sackett DL, Roberts RS An assessment of clinically useful measures of the consecuences of treatment. N Engl J Med 1988; 318: 1.728-1.733.
33. Cook RJ, Sacket DL The nuber needed to treat: a clinically useful measure of treatment effect. Br Med J 1995; 310: 452-454.
34. Hopkins A. Measuring the quality of medical care. Londres: Royal College of Physicians of London, 1990.
35. Manninen V, Elo MO, Frick MH, Haapta K, Heinonen OP, Heinsalmi P et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-651.
36. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J 1993; 306: 1.367-1.373.
37. Frank JW, Reed DM, Grove JS, Benfante R. Will lowering population levels of serum cholesterol affect total mortality? Expectations from the Honolulu Heart Program. J Clin Epidemiol 1992; 45: 333-346.
38. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Br Med J 1994; 308: 373-379.
39. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989; 320: 904-910.
40. Field K, Throgood M, Silagy C, Normand C, O'Neill C, Muir J. Strategies for reducing coronary risk factors in primary care: which is most cost effective? Br Med J 1995; 310: 1.109-1.112.
41. Kristiansen IS, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? Br Med J 1991; 302: 1.119-1.122.
42. Rosser WW. Advising patients about low-fat diets. Can Fam Physician 1993; 39: 75-80.
43. Grundy SM. Cholesterol and coronary heart disease. Future directions. JAMA 1990; 264: 3.053-3.059.
44. Rich-Edwards JW, Manson JE, Henneken CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1.758-1.766.
45. Russell LB. Educated guesses. Making policy about medical screening tests. Berkeley: University of Califonia Press, 1994.
46. Taylor WC, Pass TM, Shepard DS, Komaroff AL. Cholesterol reduction and life expectancy: a model incorporating multiple risk factors. Ann Intern Med 1987; 106: 605-614.
47. Martinez MA, Bueno A, Fernández MA, Garcia M, Delgado M, Gálvez R. Prevalencia de los factures de riesgo cardiovascular en poblacićn laboral. Med Clin (Barc) 1995; 105: 321-326.
48. Banegas JR, Rodríguez Artalejo F, Graciani A, Hernández Vacino R, Rey J. Trends in ischaemic heart disease mortality and its determinants in Spain, 1940-1988. Eur J Public Health 1995; 5: 50-55.
49. Calero S. Estudio coste-efectividad del tratamiento hipolipidemiante en el Sector Sanitario de Sabadell. En: Màster Economia de la Salut i Gestió Sanitària. Barcelona: Universitat de Barcelona, 1995; 21-25.
50. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeuticclass wars. Drug promotion in a competitive marketplace. N Engl J Med 1994; 331: 1.350-1.353.
51. Olalla JF, Gérvas J. Relaciones entre la industria farmacéutica y los profesionales sanitarios. Gac Sanit 1989; 3: 389-391.
52. Camí J. Promoción de medicamentos, promoción cientifica y conflicto de intereses. A propósito del Real Decreto 1416/1994, por el que se regula la publicidad de medicamentos. Gac Sanit 1995; 9: 273-275.
53. Hays TM, Alley LA, Harding KJ, Owen PA. Continuing education for general practice and the role of the pharmaceutical industry, Br J Gen Practice 1990; 40: 510-512.
54. Sheldon TA, Smith GD. Consensus conferences as drug promotion. Lancet 1993; 341: 100-102.
55. Clavero J. La investigación bajo sospecha. Quadern CAPS 1991; 15: 55-64.